Enrolling By Invitation NA INTERVENTIONAL 2-arm
NCT07336615
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals
Sponsor: ClostraBio Inc.
Conditions
Gastrointestinal Overweight , Obesity
Updated 1 time since 2026 Last updated: Dec 30, 2025 Started: Oct 9, 2025 Primary completion: Feb 26, 2026 Completion: Mar 26, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on Gastrointestinal and Overweight , Obesity, this trial is ongoing. The trial is conducted by ClostraBio Inc. and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Enrolling By Invitation — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- ClostraBio Inc.
Data source: ClostraBio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .